drugset / Trial / NCT01845792

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

NCT01845792

RandomizedSingle-groupOpen-labelTreatment

Summary

Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments. If they join this study they will receive a new combination of drugs that are used to treat prostate cancer.

Timeline

Start
2013-07
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule Oral
Subject Cabazitaxel Other / unclassified Intravenous
Background Prednisone Other / unclassified Oral

Indications